<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863132</url>
  </required_header>
  <id_info>
    <org_study_id>REBOOT-PARADOX</org_study_id>
    <nct_id>NCT03863132</nct_id>
  </id_info>
  <brief_title>accuRate Evaluation of Benefit With Optimal Medical Treatment With or With-Out Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis - REBOOT-PARADOX</brief_title>
  <acronym>REBOOT-PARADOX</acronym>
  <official_title>Optimal Medical Treatment With or Without Valve Repair in Patients With Symptomatic Paradoxical Low-Flow, Low-Gradient Aortic Stenosis - a Multi-center, Randomized Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IHF GmbH - Institut für Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IHF GmbH - Institut für Herzinfarktforschung</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic
      valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stenosis of the aortic valve leads to a narrowing of the valve, consequently to low blood
      flow from the heart into the Aorta, and is associated with symptoms like fatigue,
      breathlessness, dizziness, fainting, and chest pain. For many of the patients suffering from
      severe aortic stenosis surgical or catheter-assisted repair or replacement of the damaged
      aortic valve has been proven to be a safe and effective treatment option.

      Probably about 20-30% of patients suffering from severe aortic stenosis display a deviation
      from the usually observed disease pattern: These patients do not show the typical high
      pressure difference between the left ventricle (heart chamber) and the aorta (transvalvular
      gradient; &quot;paradoxical&quot; low flow/low gradient aortic stenosis). For these patients it is not
      yet clear, if microsurgical repair of the aortic valve (transcatheter aortic valve repair -
      TAVR) should be a treatment option as well.

      REBOOT-PARADOX evaluates whether TAVR is advantageous compared to optimal medical Treatment
      alone for patients suffering from paradoxical aortic stenosis. Two thirds of the
      participating patients will be treated by TAVR, one third will receive medical Treatment
      alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, controlled, randomized (2:1), parallel group, open-label, multi-centre, international</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death</measure>
    <time_frame>24 months after last-patient-in</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>5 years after index treatment</time_frame>
    <description>Death because of cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization due to heart failure</measure>
    <time_frame>5 years after index treatment</time_frame>
    <description>Number of hospital stays after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neurological events - incidence of strokes</measure>
    <time_frame>5 years after randomization</time_frame>
    <description>Number of strokes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neurological Events - incidence of transient ischaemic attacks</measure>
    <time_frame>5 years after randomization</time_frame>
    <description>Number of transient ischaemic attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac functionality - left ventricular function</measure>
    <time_frame>5 years after randomization</time_frame>
    <description>Echocardiographic measurement of left ventricular ejection fraction in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac functionality - aortic valve hemodynamics</measure>
    <time_frame>5 years after randomization</time_frame>
    <description>Measurement of aortic pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life</measure>
    <time_frame>5 years after randomization</time_frame>
    <description>EQ5D-score in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device reliability</measure>
    <time_frame>5 years after randomization</time_frame>
    <description>Number of reinterventions (TAVR arm only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">783</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated by transcatheter aortic valve repair (TAVR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Treatment Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive optimal medical treatment alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVR</intervention_name>
    <description>Repair of defective aortic valve by microsurgical Intervention.</description>
    <arm_group_label>TAVR Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  I1. Patients with symptomatic native aortic valve stenosis and age ≥18 years

          -  I2. Aortic valve area (AVA) ≤ 1 cm2 or indexed AVA ≤ 0.6 cm2/m2, mean aortic gradient
             &lt; 40 mmHg and stroke volume index (SVI) &lt; 35ml/m2

          -  I3. Left ventricular ejection fraction ≥ 50%

          -  I4. MDCT aortic valve calcium score men &gt; 2000AU, women &gt; 1200AU OR the likelihood
             criteria are fulfilled (symptoms without other explanation and LV hypertrophy; age &lt;
             70 yrs., AVS &lt; 0.8 cm2; SVI &lt; 35ml/m2 confirmed by 3D TOE, MRI or invasive; reduced LV
             longitudinal function without other reason)

          -  I5. Heart team agrees on eligibility for TAVR

          -  I6. Written informed consent

          -  I7. Negative pregnancy test in women with childbearing potential

        Exclusion Criteria:

          -  E1. Hemodynamic instability

          -  E2. Cardiogenic shock

          -  E3. Pre-existing mechanical or bio-prosthetic valve in any position

          -  E4. Concomitant severe valvular heart disease

          -  E5. Pre-existing or active endocarditis

          -  E6. Need for heart surgery due to other conditions

          -  E7. Aortic valve is congenital unicuspid or congenital bicuspid

          -  E8. Hypertrophic cardiomyopathy with or without obstruction

          -  E9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation

          -  E10. Acute myocardial infarction within 1 month before intended AS-treatment

          -  E11. Renal replacement therapy

          -  E12. Estimated life expectancy &lt; 24 months (730 days) due to carcinomas end stage
             liver disease or renal disease

          -  E13. Currently participating in an investigational drug or another device study. Note:
             Trials requiring extended follow‐up for products that were investigational, but have
             since become commercially available, are not considered investigational trials.

          -  E14. Patient refuses aortic valve repair
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Claas, Dr.</last_name>
    <phone>+49062159577</phone>
    <phone_ext>268</phone_ext>
    <email>claas@ihf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcel Kunadt, Dr.</last_name>
    <phone>+49062159577</phone>
    <phone_ext>223</phone_ext>
    <email>kunadt@ihf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julinda Mehilli, Prof. Dr.</last_name>
      <phone>+49 89 4400</phone>
      <phone_ext>73093</phone_ext>
      <email>Julinda.Mehilli@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Steffen Massber, Prof. Dr.</last_name>
      <phone>+49 89 4400</phone>
      <phone_ext>78870</phone_ext>
      <email>Direktion-Med1@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic stenosis</keyword>
  <keyword>Low flow</keyword>
  <keyword>Low gradient</keyword>
  <keyword>Transcatheter aortic valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

